Transcatheter Aortic Valve Implantation: What Lies Ahead?

Authors

  • Nicolo Piazza Erasmus MC, Rotterdam, Netherlands
  • Apostolos Tzikas Erasmus MC, Rotterdam, Netherlands
  • Peter De Jaegere Erasmus MC, Rotterdam, Netherlands
  • Patrick W Serruys Erasmus MC, Rotterdam, Netherlands

DOI:

https://doi.org/10.2015/hc.v5i2.219

Abstract

  Ttranscatheter aortic valve implantation (TAVI) is currently reserved for high surgical risk or inoperable patients. In 2007, TAVI actually represented approximately 1.2% of all aortic valve procedures in Europe; this percentage increased to 6.5% in 2008. With an expectation of ~9000 TAVI procedures to be performed in 2009, TAVI may represent nearly13% of all aortic valve procedures. It is forecasted that by 2012 transcatheter valve therapies will account for approximately 40% of the total heart valve procedures performed in Europe. One major limiting factor relates to procedural complications of TAVI. Conduction abnormalities and the need for permanent pacemaker, paravalvular aortic regurgitation, stroke and vascular complications have received particular attention. The future and widespread adoption of TAVI will rely on a number of inter-related factors, including long-term durability and safety data, randomized controlled trials comparing TAVI with surgical aortic valve replacement and reimbursement for the technology.

Author Biographies

Nicolo Piazza, Erasmus MC, Rotterdam, Netherlands

Specialty: Cardiology

Apostolos Tzikas, Erasmus MC, Rotterdam, Netherlands

Interventional Cardiology

Peter De Jaegere, Erasmus MC, Rotterdam, Netherlands

Interventional Cardiology

Patrick W Serruys, Erasmus MC, Rotterdam, Netherlands

Interventional Cardiology

Downloads

Issue

Section

REVIEWS